Результаты поиска

A call for the United States to continue investing in science.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Year | Development a | Outcome 1990–2003 | Human Genome Project | Personalized medicine (e.g. targeted therapies for breast cancer, including HER2 inhibitors like Herceptin, and chronic myeloid leukemia [Gleevec]) 1990–present | Targeted cancer therapies | Immunotherapy (e.g. checkpoint inhibitors like …

A call for the United States to continue investing in science.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Year | Development a | Outcome 1990–2003 | Human Genome Project | Personalized medicine (e.g. targeted therapies for breast cancer, including HER2 inhibitors like Herceptin, and chronic myeloid leukemia [Gleevec]) 1990–present | Targeted cancer therapies | Immunotherapy (e.g. checkpoint inhibitors like …

Complement C3a activates osteoclasts by regulating the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma.

ObjectiveMyeloma bone disease (MBD) is the most common complication of multiple myeloma (MM). Our previous study showed that the serum levels of C3/C4 in MM patients were significantly positively correlated with the severity of bone disease. However, the mechanism of C3a/C4a in osteoclasts MM patients remains unclear.MethodsThe formation and function of osteoclasts were analyzed after adding C3a/C4a in vitro. RNA-seq analysis was used to screen the potential pathways affecting osteoclasts, and the results were verified by Western blot, qRT-PCR, and pathway inhibitors.ResultsThe osteoclast area

A call for the United States to continue investing in science.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Year | Development a | Outcome 1990–2003 | Human Genome Project | Personalized medicine (e.g. targeted therapies for breast cancer, including HER2 inhibitors like Herceptin, and chronic myeloid leukemia [Gleevec]) 1990–present | Targeted cancer therapies | Immunotherapy (e.g. checkpoint inhibitors like …

A call for the United States to continue investing in science.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Year | Development a | Outcome 1990–2003 | Human Genome Project | Personalized medicine (e.g. targeted therapies for breast cancer, including HER2 inhibitors like Herceptin, and chronic myeloid leukemia [Gleevec]) 1990–present | Targeted cancer therapies | Immunotherapy (e.g. checkpoint inhibitors like …

A call for the United States to continue investing in science.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Year | Development a | Outcome 1990–2003 | Human Genome Project | Personalized medicine (e.g. targeted therapies for breast cancer, including HER2 inhibitors like Herceptin, and chronic myeloid leukemia [Gleevec]) 1990–present | Targeted cancer therapies | Immunotherapy (e.g. checkpoint inhibitors like …

A call for the United States to continue investing in science.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Year | Development a | Outcome 1990–2003 | Human Genome Project | Personalized medicine (e.g. targeted therapies for breast cancer, including HER2 inhibitors like Herceptin, and chronic myeloid leukemia [Gleevec]) 1990–present | Targeted cancer therapies | Immunotherapy (e.g. checkpoint inhibitors like …

A call for the United States to continue investing in science.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Year | Development a | Outcome 1990–2003 | Human Genome Project | Personalized medicine (e.g. targeted therapies for breast cancer, including HER2 inhibitors like Herceptin, and chronic myeloid leukemia [Gleevec]) 1990–present | Targeted cancer therapies | Immunotherapy (e.g. checkpoint inhibitors like …

A call for the United States to continue investing in science.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Year | Development a | Outcome 1990–2003 | Human Genome Project | Personalized medicine (e.g. targeted therapies for breast cancer, including HER2 inhibitors like Herceptin, and chronic myeloid leukemia [Gleevec]) 1990–present | Targeted cancer therapies | Immunotherapy (e.g. checkpoint inhibitors like …

[Retracted] miR‑23a suppresses pancreatic cancer cell progression by inhibiting PLK‑1 expression.

BACKGROUND: One presentation of Avoidant/Restrictive Food Intake Disorder (ARFID) is characterized by picky eating, i.e., selective eating based on the sensory properties of food. The present study has two aims. The first is to describe distress and impairment in individuals with ARFID secondary to picky eating. The second is to determine whether eating behaviors hypothesized to be specific to picky eating can differentiate picky eaters with and without ARFID from typical eaters (e.g., individuals not reporting picky or disordered eating) and individuals who strongly endorse attitudes associat

Совпадение в полном тексте источника
… Genome Project (SGHP) is an initiative that aims to describe the genetic distribution of cancer within Saudi Arabia, and this has been joined by programmes from Qatar, Egypt and the United Arab Emirates (Fig. 1 ). … Supplementary information Reporting Summary Acknowledgements The author thanks King Abdulaziz City for Science and Technology and the Saudi Human Genome Project for technical support. This study was funded by King Fahad Medical City (IRF 17-17) (M.A.). …

Allele-specific vitamin D receptor binding is associated with pediatric-onset multiple sclerosis.

BACKGROUND AND OBJECTIVES: The genetic basis of adult-onset multiple sclerosis (MS) is well-studied, but less is known about pediatric-onset MS (pedMS), comprising approximately 5% of all MS onsets. Mendelian randomization (MR) studies have demonstrated evidence for a causal association between MS and both 25-hydroxyvitamin D [25(OH)D] serum levels and genetic variation related to vitamin D receptor (VDR) binding. The objective was to identify whether VDR binding variants (VDR-BVs) previously implicated in adult-onset MS were associated with pedMS using genetic instrumental variables (GIVs).

DIGGER 2.0: digging into the functional impact of differential splicing on human and mouse disorders.

Changes in alternative splicing between groups or conditions contribute to protein-protein interaction rewiring, a consequence often neglected in data analysis. The web server and database DIGGER overcomes this limitation by augmenting a protein-protein interaction network with domain-domain interactions and splicing information. Here, we present DIGGER 2.0, which now features both experimental and newly added predicted domain-domain interactions. In addition to the human interactome, DIGGER 2.0 adds support for mouse as an important model organism. Additionally, we integrated the splicing ana

Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances.

The high expression of CD7 targets in T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoma has attracted considerable attention from researchers. However, because CD7 chimeric antigen receptor (CAR) T-cells undergo fratricide, CD7 CAR T-cells develop an exhaustion phenotype that impairs the effect of CAR T-cells. There have been significant breakthroughs in CD7-targeted CAR T-cell therapy in the past few years. The advent of gene editing, protein blockers, and other approaches has effectively overcome the adverse effects of conventional methods of CD7 CAR T-cells. This review, in conjunc

Heterogeneity in precision oncology.

Precision oncology is a rapidly evolving concept that holds great promise in cancer treatment. However, a cancer complexity attributed to genomic and acquired tumour heterogeneity limits treatment effectiveness and increases toxicity. These limitations refer to both systemic therapies and radiotherapy, which are two mainstays of non-invasive cancer treatment. By understanding cancer heterogeneity and utilising advanced tools to personalise treatment strategies, precision oncology has the potential to revolutionise cancer care. In this article, we review the current status of precision oncology

Prognostic impact of biomarkers in PMBCL: rationale for early integration of immune checkpoint inhibitors.

AimThis research aims to guide future strategies for personalized treatment of primary mediastinal large B-cell lymphoma (PMBCL), particularly to identify high-risk patients who may benefit from incorporating immune checkpoint inhibitors (ICIs) in the first-line setting.MethodsA retrospective, single-center study included 254 newly diagnosed PMBCL patients treated with rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (R-DA-EPOCH), rituximab, modified protocol NHL-BFM-90 (RmNHL-BFM-90), or R-DA-EPOCH combined with nivolumab. Clinical parameters, immunoh

Small RNA Sequencing Identifies PIWI-Interacting RNAs Deregulated in Glioblastoma-piR-9491 and piR-12488 Reduce Tumor Cell Colonies In Vitro.

Glioblastoma (GBM) is the most frequently occurring primary malignant brain tumor of astrocytic origin. To change poor prognosis, it is necessary to deeply understand the molecular mechanisms of gliomagenesis and identify new potential biomarkers and therapeutic targets. PIWI-interacting RNAs (piRNAs) help in maintaining genome stability, and their deregulation has already been observed in many tumors. Recent studies suggest that these molecules could also play an important role in the glioma biology. To determine GBM-associated piRNAs, we performed small RNA sequencing analysis in the discove

Clonotypic characterization defines B-cell drivers of clonal expansion and intratumor heterogeneity in IgM monoclonal gammopathies.

Waldenström macroglobulinemia (WM) and IgM monoclonal gammopathy of undetermined significance (MGUS) share the same cell of origin but differ in clonal size. Compared with other B-cell neoplasms, the lymphoplasmacytic clone in WM can be rather small, limiting our understanding of clonal expansion. We applied an integrative approach using single-cell RNA with B-cell receptor (BCR) sequencing, the assay for transposase-accessible chromatin, and whole-genome sequencing to characterize the tumor clone in patients with IgM MGUS, smoldering WM (SWM), and symptomatic WM (WM). IgM MGUS and low- or int

Оценка причинно-следственного воздействия метаболомы на риск психических и нейродегенеративных расстройств.

Данные свидетельствуют о фенотипическом и биологическом переплетении между психическими и нейродегенеративными расстройствами. Дальнейшее выявление лежащих в основе взаимных и уникальных биологических механизмов может привести к появлению новых, многопорядковых и многопорядковых терапевтических целей. Метаболом представляет собой важную область для идентификации целей, поскольку метаболиты играют важнейшую роль в модуляции разнообразных биологических процессов.Мы использовали менделианскую случайность (MR) для проверки причинного воздействия ~ 1000 плазменных метаболитов и ~ 300 метаболитов на

Более широкие соображения в отношении интеграции медицинских и стоматологических данных

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Diagnostic and prognostic values of integrin α subfamily mRNA expression in colon adenocarcinoma.

The integrin α (ITGA) subfamily genes play a fundamental role in various cancers. However, the potential mechanism and application values of ITGA genes in colon adenocarcinoma (COAD) remain elusive. The present study investigated the significance of the expression of ITGA genes in COAD from the perspective of diagnosis and prognosis. A COAD RNA‑sequencing dataset was obtained from The Cancer Genome Atlas. The present study investigated the biological function of the ITGA subfamily genes through bioinformatics analysis. Reverse transcription‑quantitative polymerase chain reaction was applied to